DWA
ZVRA icon

Dorsey Wright & Associates’s Zevra Therapeutics ZVRA Stock Holding History

Dorsey Wright & Associates’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,932
Closed -$19K – 292
2023
Q3 		$19K Sell
3,932
-136
-3% -$679 0.01% 260
2023
Q2 		$20.7K Buy
+4,068
New +$21.9K 0.01% 256

Other funds holding ZVRA

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Dorsey Wright & Associates's ZVRA Position: Q4 2023 in Review

Dorsey Wright & Associates sold out of Zevra Therapeutics (ZVRA) in Q4 2023, closing a stake of 3,932 shares — an estimated $19K sold.

Dorsey Wright & Associates first reported a position in ZVRA in Q2 2023 and held it in 2 quarters. The position peaked at $20.7K in Q2 2023. 84 funds tracked by Wall St. Rank hold ZVRA as of Q4 2023.

  • Dorsey Wright & Associates reported no remaining Zevra Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 3,932 Zevra Therapeutics shares in Q4 2023, an estimated $19K.
  • Dorsey Wright & Associates first reported a position in Zevra Therapeutics in Q2 2023 and held it in 2 quarters.
  • Dorsey Wright & Associates's Zevra Therapeutics position peaked at $20.7K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2023.

Based on Dorsey Wright & Associates's 13F filing for Q4 2023, filed 13 Feb 2024.